Esperion Therapeutics Secures $33,000,000 New Funding Round

  • Feed Type
  • Date
    4/25/2013
  • Company Name
    Esperion Therapeutics
  • Mailing Address
    46701 Commerce Center Drive Plymouth, MI 48170
  • Company Description
    Esperion Therapeutics, Inc. discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called HDL Therapy, which is based on the Company’s understanding of high-density lipoprotein, or HDL, function.
  • Website
    http://www.esperion.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $33,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    We intend to use this financing to advance ETC-1002 through the next important phase of development.
  • M&A Terms
  • Venture Investor
    Longitude Capital Management
  • Venture Investor
    Aisling Capital
  • Venture Investor
    Alta Partners
  • Venture Investor
    Domain Associates
  • Venture Investor
    Asset Management Company
  • Venture Investor
    Arboretum Ventures

By posting a comment, you agree to our terms and conditions.